Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HDM2 phosphorylation by MAPKAP kinase 2.

Hans Oliver Weber1, Robert L Ludwig, Deborah Morrison

  • 1The Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK.

Oncogene
|February 3, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MK2/p38/p53 Suppress Basal IL-1β and Non-Canonical NF-κB Signaling in Macrophages.

International journal of molecular sciences·2026
Same author

ALDH1L2 regulates reactive oxygen species and acinar-to-ductal metaplasia in the pancreas.

Nature metabolism·2026
Same author

Cell Clustering Promotes a Metabolic Switch that Supports Metastatic Colonization.

Cell metabolism·2026
Same author

In conversation with Karen Vousden.

The FEBS journal·2026
Same author

Repeat-associated non-AUG translation as a common mechanism for the polyGln ataxias.

Cell reports·2025
Same author

Repeat associated non-AUG translation as a common mechanism for the polyGln ataxias.

bioRxiv : the preprint server for biology·2025
Same journal

SRD5A3-mediated aberrant N-glycosylation of SCARA5 promotes ferroptosis in lung adenocarcinoma.

Oncogene·2026
Same journal

Aberrant splicing in human cancer shows possible functional impact on transcription factors.

Oncogene·2026
Same journal

The crosstalk between RNA m6A modification and protein lactylation: emerging insights into tumor progression.

Oncogene·2026
Same journal

Correction: Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway.

Oncogene·2026
Same journal

Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.

Oncogene·2026
Same journal

Histone lactylation-driven IGF2BP3 promotes intrahepatic cholangiocarcinoma progression via SPP1/CD44-dependent macrophage polarization.

Oncogene·2026
See all related articles

MAPKAP kinase 2 (MK2) phosphorylates HDM2, a key regulator of p53 stability. This phosphorylation influences p53 degradation, suggesting MK2 dampens the p53 response.

Area of Science:

  • Molecular Biology
  • Cellular Signaling
  • Cancer Research

Background:

  • p53 protein stability is tightly regulated by HDM2, an E3 ligase.
  • HDM2 targets p53 for ubiquitination and subsequent degradation.
  • AKT-mediated phosphorylation of HDM2 enhances its activity and promotes p53 degradation.

Purpose of the Study:

  • To investigate the role of MAPKAP kinase 2 (MK2) in regulating HDM2 activity.
  • To determine if MK2 phosphorylates HDM2 and affects p53 stability.

Main Methods:

  • In vitro kinase assays to assess MK2 phosphorylation of HDM2.
  • Cellular treatments with anisomycin to activate MK2 in vivo.
  • Site-directed mutagenesis of HDM2 phosphorylation sites.
  • Analysis of p53 and Mdm2 protein levels in MK2-deficient cells.

Related Experiment Videos

Main Results:

  • MK2 phosphorylates HDM2 on serine 157 and 166 in vitro.
  • Anisomycin treatment leads to in vivo phosphorylation of HDM2 on serine 157 and 166.
  • Mutating these sites in HDM2 enhances p53 degradation.
  • MK2-deficient cells exhibit reduced Mdm2 phosphorylation and increased p53 levels.

Conclusions:

  • MK2 phosphorylates HDM2 at specific sites, influencing its E3 ligase activity.
  • MK2 activity appears to modulate the p53 tumor suppressor response.
  • These findings suggest MK2 acts as a negative regulator of the p53 pathway.